HUMAN RECOMBINANT GPR17 (SHORT FORM) RECEPTOR
MULTISCREEN™ STABLE CELL LINES
1 vial (2 x 106) frozen cells
Expression vector containing full-length human GPR17 cDNA (GenBank Accession Number NM_001161416.1) with FLAG tag sequence at N-terminus
Liquid nitrogen upon receiving
Propagation Medium: DMEM, 10% FBS, 1 μg/mL puromycin
Stable for a minimum of 2 months in continuous culture
Background: G-protein coupled receptor 17 (GPR17) is closely related to the purinergic and cysteinyl-leukotriene receptor families. It is present on both neurons and a subset of oligiodendrocyte precursor cells. Recent studies have shown that GPR17 plays an important role in both sensing and repairing brain damage. Thus, GPR17 represents a potential new target for the treatment of traumatic brain injuries as well as neurodegenerative diseases like Alzheimer’s and multiple sclerosis.
Application: Functional assays
Figure 1. Dose-dependent stimulation of calcium flux upon treatment with ligand, measured with MultiscreenTM Calcium 1.0 No Wash Assay Kit (Multispan MSCA01). Figure 2. Dose-dependent inhibition of forskolin-stimulated intracellular cAMP level upon treatment with ligand, measured with MultiscreenTM TR-FRET cAMP 1.0 No Wash Assay Kit (Multispan MSCM01). Figure 3. Receptor expression on cell surface measured by flow cytometry (FACS) using an anti-FLAG antibody. Thin line: parental cells; thick line: receptor-expressing cells.
Franke, Heike et al. “Changes of the GPR17 Receptor, a New Target for Neurorepair, in Neurons and Glial Cells in Patients with Traumatic Brain Injury.” Purinergic Signalling 9.3 (2013): 451–462. PMC. Web. 18 Feb. 2015.